Intelligent Lowe Syndrome Treatment System

Publication ID: 24-11857549_0008_PTD
Published: October 28, 2025
Category:Synergistic Combinations

Legal Citation

pr1or.art Inc., “Intelligent Lowe Syndrome Treatment System,” Published Technical Disclosure No. 24-11857549_0008_PTD, Published October 28, 2025, available at https://archive.pr1or.art/24-11857549_0008_PTD
This technical disclosure describes improvements that would be readily apparent to a Person Having Ordinary Skill In The Art (PHOSITA) when considered in combination with the foundational architecture disclosed in U.S. Patent No. 11,857,549.

Summary of the Inventive Concept

A novel, integrated system for treating Lowe Syndrome, combining RhoA inhibitors, statins, and mTOR inhibitors with AI, IoT, blockchain, and nanomaterial technologies to enhance treatment efficacy, personalization, and patient data management.

Background and Problem Solved

Lowe Syndrome, a devastating genetic disease, lacks effective treatments. The original patent's compositions and methods, while promising, have limitations in terms of treatment monitoring, patient data management, and personalized treatment. This inventive concept addresses these limitations by integrating the patented inventive concept with distinct technologies to create a more powerful system.

Detailed Description of the Inventive Concept

The Intelligent Lowe Syndrome Treatment System comprises a RhoA inhibitor, a statin, a mTOR inhibitor, and an AI-powered diagnostic tool for monitoring treatment efficacy. The system also utilizes blockchain technology to securely store and track patient data, enabling personalized treatment and remote monitoring. Additionally, the system incorporates a nanomaterial-based delivery system for targeted release of the therapeutic agents. The IoT device tracks patient symptoms, and a cloud-based analytics platform analyzes patient data to provide personalized treatment recommendations. Machine learning algorithms predict treatment outcomes, identifying optimal treatment combinations.

Novelty and Inventive Step

The integration of AI, IoT, blockchain, and nanomaterial technologies with the patented inventive concept is new and non-obvious, providing a synergistic combination that enhances treatment efficacy, personalization, and patient data management.

Alternative Embodiments and Variations

Alternative embodiments may include using different AI algorithms, IoT devices, or blockchain platforms. Variations may involve incorporating other distinct technologies, such as gene editing or bioprinting, to further enhance the system's capabilities.

Potential Commercial Applications and Market

The Intelligent Lowe Syndrome Treatment System has significant commercial potential in the pharmaceutical and healthcare industries, offering a novel solution for treating a devastating genetic disease. The system's personalized approach, remote monitoring capabilities, and secure data management features make it an attractive solution for patients, clinicians, and payers.

Field of Art

Medical biotechnology, pharmaceutical composition design, genetic disease treatment, with expertise in computational healthcare technologies and personalized medicine approaches

Person of Ordinary Skill (PHOSITA) Profile

A professional with advanced degrees in biotechnology or pharmaceutical sciences, understanding genetic disease mechanisms, drug delivery systems, and emerging digital health technologies, capable of integrating multiple technological domains

Obviousness Rationale

A PHOSITA would recognize that integrating digital technologies with established pharmaceutical treatments represents a predictable evolution of personalized medicine. The source patent's foundational treatment approach for Lowe Syndrome provides a clear technological framework that naturally invites computational and data-driven enhancements. The PTD's proposed technological integrations represent logical extensions of existing treatment paradigms, utilizing well-established techniques in AI, IoT, and data management to optimize therapeutic outcomes.

Obvious Combinations & Variations

Source Patent Element
Pharmaceutical composition combining rosuvastatin and rapamycin for Lowe Syndrome treatment
PTD Variation
Adding AI-powered diagnostic tool for monitoring treatment efficacy
Obviousness Reasoning
Predictable application of computational monitoring to existing pharmaceutical treatment, representing a known technique in personalized medicine for tracking therapeutic responses
Source Patent Element
Pharmaceutical treatment targeting specific genetic syndrome
PTD Variation
Incorporating blockchain technology for secure patient data management
Obviousness Reasoning
Routine implementation of data security technologies in medical treatment tracking, representing a standard design choice in digital health systems
Source Patent Element
Pharmaceutical composition for genetic disease treatment
PTD Variation
Nanomaterial-based targeted delivery system for therapeutic agents
Obviousness Reasoning
Well-known technique in pharmaceutical sciences for improving drug delivery precision, representing a predictable optimization of existing treatment methodologies
Source Patent Element
Treatment method for genetic syndrome
PTD Variation
IoT device for remote symptom tracking and cloud-based analytics platform
Obviousness Reasoning
Standard technological progression in telemedicine and personalized healthcare monitoring, representing an obvious extension of existing treatment paradigms
Source Patent Element
Pharmaceutical composition targeting specific genetic mechanisms
PTD Variation
Machine learning algorithms for predicting treatment outcomes
Obviousness Reasoning
Predictable application of computational predictive modeling to medical treatment optimization, representing a known technique in data-driven healthcare
35 U.S.C. § 103 Summary: Based on US Patent 11857549's foundational disclosure of Lowe Syndrome treatment compositions, the present publication demonstrates that a person of ordinary skill in the art would find the integration of digital health technologies, AI-driven monitoring, and advanced drug delivery systems an obvious and predictable extension of existing pharmaceutical treatment methodologies, thereby rendering subsequent claims of novelty invalid under standard obviousness criteria.

Original Patent Information

Patent NumberUS 11,857,549
TitleCompositions and methods for the treatment of Lowe syndrome
Assignee(s)Purdue Research Foundation